iqvia glp-1 prescriptions semaglutide tirzepatide q3 2024 prescription trends through June Biopharma report 2024: Three's company

A composite outcome of (1) an HbA1c 6.5% together with (2) 10% WL and (3) without episodes of severe or clinically significant hypoglycemia was achieved by 22% of participants at the semaglutide 1 mg group, compared to 32% to 60% at the tirzepatide 5 to 15 mg groups after 40 weeks of treatment, demonstrating the potential of tirzepatide to improve further the current management of people with T2DM and obesity compared to the currently used GLP-1 RAs

However, its effects may go beyond just regulating blood sugar and appetite

Always discuss with your doctor what combination aligns with your training cycle and recovery needs

En esta presentacin, la Dra